Responsiveness of skin metastases to CMF in a patient with urothelial carcinoma of the bladder: a case report.
Skin metastases from urothelial carcinoma of the bladder are uncommon, and there are few cases reported in literature. The present case report describes the results of a combination of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) administered as second-line chemotherapy in a cisplatin-resistant metastatic bladder cancer patient. The improvement in cutaneous lesions and pain reduction obtained prompt further exploration of the activity of this regimen in a second-line approach.
Rosati
Gerardo
G
UO Oncologia Medica, Ospedale S Carlo, Potenza, Italy. rosatiger@yahoo.com
Rossi
Antonio
A
Germano
Domenico
D
Piccirillo
Angelo
A
De Sanctis
Domenico
D
Manzione
Luigi
L
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000556:secondary*; D002945:Cisplatin / Q000494:pharmacology; D003520:Cyclophosphamide / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000473:pathology*; D019459:Urothelium / Q000473:pathology
D003520:Cyclophosphamide; D002945:Cisplatin; D005472:Fluorouracil; D008727:Methotrexate